Literature DB >> 20233178

Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Janne Hukkanen1, Peyton Jacob Iii, Margaret Peng, Delia Dempsey, Neal L Benowitz.   

Abstract

AIMS: Smoking slows the metabolism of nicotine and accelerates the metabolism of chlorzoxazone, which are probe reactions for cytochrome P450 2A6 (CYP2A6) and CYP2E1 activities, respectively. We aimed to determine the role of nicotine in these metabolic effects of cigarette smoking.
METHODS: The study had a single-blind, randomized, crossover two-arm design. Twelve healthy smokers were given two transdermal patches with 42-mg nicotine a day or placebo patches, each for 10 days. The subjects abstained from smoking during the study arms. Oral chlorzoxazone was given on day 7 and deuterium-labelled nicotine-d(2) and cotinine-d(4) infusion on day 8.
RESULTS: There was no significant influence of transdermal nicotine administration on pharmacokinetic parameters of nicotine-d(2) or on the formation of cotinine-d(2). Nicotine decreased the volume of distribution (62.6 vs. 67.7 l, 95% confidence interval of the difference -9.7, -0.6, P= 0.047) of infused cotinine-d(4). There were no significant differences in disposition kinetics of chlorzoxazone between the treatments.
CONCLUSIONS: CYP2A6 and CYP2E1 activities are not affected by nicotine. The tobacco smoke constituents responsible for the reduced CYP2A6 and increased CYP2E1 activities remain unknown.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233178      PMCID: PMC2824476          DOI: 10.1111/j.1365-2125.2009.03568.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

1.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.

Authors:  Kerri A Schoedel; Edward M Sellers; Roberta Palmour; Rachel F Tyndale
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

2.  Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro.

Authors:  T R Van Vleet; D W Bombick; R A Coulombe
Journal:  Toxicol Sci       Date:  2001-12       Impact factor: 4.849

3.  Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  2000-06       Impact factor: 6.875

Review 4.  Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments.

Authors:  D Lucas; R Ferrara; E Gonzales; A Albores; M Manno; F Berthou
Journal:  Toxicol Lett       Date:  2001-10-15       Impact factor: 4.372

5.  High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.

Authors:  H Z Bu; L Magis; K Knuth; P Teitelbaum
Journal:  Rapid Commun Mass Spectrom       Date:  2001       Impact factor: 2.419

6.  Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics.

Authors:  Lisa A Howard; Sharon Miksys; Ewa Hoffmann; Deborah Mash; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

7.  Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver.

Authors:  L A Howard; A L Micu; E M Sellers; R F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

8.  Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake.

Authors:  Jiang Yue; Jibran Khokhar; Sharon Miksys; Rachel F Tyndale
Journal:  Eur J Pharmacol       Date:  2009-03-13       Impact factor: 4.432

9.  Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism.

Authors:  Alina L Micu; Sharon Miksys; Edward M Sellers; Dennis R Koop; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2003-05-15       Impact factor: 4.030

10.  Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.

Authors:  Neal L Benowitz; Margaret Peng; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more
  5 in total

1.  Effect of nicotine on cytochrome P450 1A2 activity.

Authors:  Janne Hukkanen; Peyton Jacob; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 2.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

3.  Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers.

Authors:  Gideon St Helen; Maciej L Goniewicz; Delia Dempsey; Margaret Wilson; Peyton Jacob; Neal L Benowitz
Journal:  Chem Res Toxicol       Date:  2012-03-29       Impact factor: 3.739

Review 4.  Effects of tobacco smoking and nicotine on cancer treatment.

Authors:  William P Petros; Islam R Younis; James N Ford; Scott A Weed
Journal:  Pharmacotherapy       Date:  2012-10       Impact factor: 4.705

5.  Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors.

Authors:  Meaghan O'Malley; Patrick Healy; Stephanie Daignault; Nithya Ramnath
Journal:  Oncology       Date:  2013-09-24       Impact factor: 2.935

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.